These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 19925842)

  • 1. Biosimilars approval process.
    Zuñiga L; Calvo B
    Regul Toxicol Pharmacol; 2010 Apr; 56(3):374-7. PubMed ID: 19925842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Similar biological medicinal products containing recombinant human growth hormone: European regulation.
    Pavlovic M; Girardin E; Kapetanovic L; Ho K; Trouvin JH
    Horm Res; 2008; 69(1):14-21. PubMed ID: 18059081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biosimilars: pharmacovigilance and risk management.
    Zuñiga L; Calvo B
    Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):661-9. PubMed ID: 20583204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative testing and pharmacovigilance of biosimilars.
    Locatelli F; Roger S
    Nephrol Dial Transplant; 2006 Oct; 21 Suppl 5():v13-6. PubMed ID: 16959789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals.
    Reeve LM
    Regul Toxicol Pharmacol; 2009 Nov; 55(2):181-7. PubMed ID: 19589365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. European regulatory guidelines for biosimilars.
    Wiecek A; Mikhail A
    Nephrol Dial Transplant; 2006 Oct; 21 Suppl 5():v17-20. PubMed ID: 16959790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statistical assessment of biosimilar products.
    Chow SC; Liu JP
    J Biopharm Stat; 2010 Jan; 20(1):10-30. PubMed ID: 20077246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Follow-on biologics: challenges of the "next generation".
    Schellekens H
    Nephrol Dial Transplant; 2005 May; 20 Suppl 4():iv31-36. PubMed ID: 15827057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-clinical safety studies on biosimilar recombinant human erythropoietin.
    Parnham MJ; Schindler-Horvat J; Kozlović M
    Basic Clin Pharmacol Toxicol; 2007 Feb; 100(2):73-83. PubMed ID: 17244255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The challenges of regulating stem cell-based products.
    von Tigerstrom BJ
    Trends Biotechnol; 2008 Dec; 26(12):653-8. PubMed ID: 18977047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Legal requirements for the quality of herbal substances and herbal preparations for the manufacturing of herbal medicinal products in the European union.
    Vlietinck A; Pieters L; Apers S
    Planta Med; 2009 Jun; 75(7):683-8. PubMed ID: 19204891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in European legislation make it timely to introduce a transparent market surveillance system for cosmetics.
    Lodén M; Ungerth L; Serup J
    Acta Derm Venereol; 2007; 87(6):485-92. PubMed ID: 17989885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The regulatory framework of biosimilars in the European Union.
    Minghetti P; Rocco P; Cilurzo F; Vecchio LD; Locatelli F
    Drug Discov Today; 2012 Jan; 17(1-2):63-70. PubMed ID: 21856438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From bioequivalence to biosimilars: How much do regulators dare?
    Weise M
    Z Evid Fortbild Qual Gesundhwes; 2019 Mar; 140():58-62. PubMed ID: 30622000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.
    Ahmed I; Kaspar B; Sharma U
    Clin Ther; 2012 Feb; 34(2):400-19. PubMed ID: 22244050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biosimilar medicines--new challenges for a new class of medicine.
    Fox A
    J Biopharm Stat; 2010 Jan; 20(1):3-9. PubMed ID: 20077245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concept of biosimilar products in Jordan.
    Haddadin RD
    Biologicals; 2011 Sep; 39(5):333-5. PubMed ID: 21873079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Biosimilars].
    Krämer I
    Ther Umsch; 2011 Nov; 68(11):659-66. PubMed ID: 22045529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presentation of the EEC directive (81/852)--quality.
    Lee AM
    Dev Biol Stand; 1992; 79():39-41. PubMed ID: 1286763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Position statements regarding usage of biosimilars of Epoetins. Position paper of the Société de néphrologie, Société francophone de dialyse, and Société de néphrologie pédiatrique].
    Bouchet JL; Brunet P; Canaud B; Chanliau J; Combe C; Deray G; Houillier P; Kourilsky O; Ledneva E; Niaudet P; Ortiz JP; Pavlovic M; Ryckelynck JP; Singlas E; Verhelst D; ; ;
    Nephrol Ther; 2009 Feb; 5(1):61-6. PubMed ID: 19084489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.